-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PLN-101095 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PLN-101095 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PLN-101095 in Solid Tumor Drug Details: PLN-101095 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBVCLS-7262 in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBVCLS-7262 in Amyotrophic Lateral Sclerosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABBVCLS-7262 in Amyotrophic Lateral Sclerosis Drug Details: ABBVCLS-7262 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bexotegrast in Primary Sclerosing Cholangitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bexotegrast in Primary Sclerosing Cholangitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bexotegrast in Primary Sclerosing Cholangitis Drug Details: Bexotegrast (PLN-74809) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bexotegrast in Liver Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bexotegrast in Liver Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bexotegrast in Liver Fibrosis Drug Details: Bexotegrast (PLN-74809) is under development...
-
Product Insights
NewNet Present Value Model: Pliant Therapeutics Inc’s Bexotegrast
Empower your strategies with our Net Present Value Model: Pliant Therapeutics Inc's Bexotegrast report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bexotegrast in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bexotegrast in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bexotegrast in Idiopathic Pulmonary Fibrosis Drug Details: Bexotegrast (PLN-74809) is...
-
Product Insights
Idiopathic Pulmonary Fibrosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Idiopathic Pulmonary Fibrosis Clinical Trial Report Overview A total of 713 idiopathic pulmonary fibrosis clinical trials were conducted as of January 2024. The Idiopathic Pulmonary Fibrosis clinical trial report provides a comprehensive understanding of the idiopathic pulmonary fibrosis clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iptacopan Hydrochloride in Atypical Hemolytic Uremic Syndrome (Nondiarrhea – Associated Hemolytic Uremic Syndrome)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Iptacopan Hydrochloride in Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) Drug Details:...
-
Product Insights
NewPrimary Sclerosing Cholangitis – Drugs In Development, 2024
Empower your strategies with our Primary Sclerosing Cholangitis – Drugs In Development, 2024 report and make more profitable business decisions. Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness, and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs. The Primary Sclerosing Cholangitis drugs in development...
-
Product Insights
NewCholangitis – Drugs In Development, 2024
Empower your strategies with our Cholangitis – Drugs In Development, 2024 report and make more profitable business decisions. Cholangitis refers to inflammation of the bile ducts, which are tubes that carry bile from the liver to the gallbladder and small intestine. This condition can be acute or chronic and is often caused by a bacterial infection or blockage of the bile ducts. Cholangitis can cause a range of symptoms, which may include abdominal pain, particularly in the upper right side; jaundice...